Pancreatic Cancer

 

IPI-926 w/ Gemcitabine for Metastatic Pancreatic Cancer (UW10026)
A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine (Gemzar) in Patients With Metastatic Pancreatic Cancer

Investigator: Samual Whiting, MD, PhD;   Conditions: Metastatic Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01130142

Combination Chemotherapy + Radiation + Surgery for Localized Pancreatic Cancer (FHCRC-6511)
A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients with Locally Advanced, Resectable Pancreatic Adenocarcinoma

Investigator: Samuel Whiting, MD, PhD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT00609336

ABI-007 for Metastatic Adenocarcinoma of the Pancreas (FHCRC-2350)
A Randomized Phase III Study of Weekly ABI-007 (Abraxane) plus Gemcitabine (Gemzar) versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas

Investigator: Sunil Hingorani, MD, PhD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT00844649

HyperAcute®-Pancreatic Cancer Vaccine for Surgically Resected Pancreatic Cancer (7259)
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute®-Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer

Investigator: Samuel Whiting, MD, PhD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01072981

PEGPH20 for Stage IV Previously Untreated Pancreatic Cancer
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine (Gemzar) Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil Hingorani, MD, PhD;   Conditions: Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01453153